Australia Neurology Devices Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035)

Market Overview

The Australia neurology devices market is moving from an import-led, hospital-centred model towards one where local innovators compete directly with global device makers. Sensing-based stimulators, implantable brain monitors and portable stroke scanners are entering the market in parallel with proven implants.

Three forces are shaping demand: an ageing population, with more than 440,000 stroke survivors living in the community; faster adoption of closed-loop and rechargeable stimulation for pain and Parkinson's disease; and public funding that targets earlier stroke diagnosis through mobile stroke units and golden hour research.

In December 2025 both Saluda Medical and Epiminder listed on the Australian Securities Exchange, and in November 2025 Synchron closed a USD 200 million round. In January 2026 Boston Scientific agreed to acquire Penumbra for an enterprise value of USD 14.5 billion.

Key Market Trends and Insights

• Stroke burden: A stroke occurs every 11 minutes in Australia, according to the Stroke Foundation's 2026 research report, which keeps demand for thrombectomy and reperfusion devices rising.
• Local listings: Saluda Medical raised A$230.8 million when it listed on 5 December 2025, giving a home-grown neurostimulation company fresh capital for Australian and European launch activity.
• Closed-loop stimulation: Saluda's EVA sensing technology received CE certification on 8 January 2026 and is recognised in Australia, with a limited release planned for the first quarter of 2026.
• Portable diagnostics: EMVision scanned 10 suspected stroke patients with the Melbourne Mobile Stroke Unit, averaging 6.7 minutes per scan, in a study reported on 16 September 2026.

Australia Neurology Devices Market Size and Forecast

The market is moving from mechanical, open-loop devices towards sensing, rechargeable and remotely programmable systems that adjust therapy to the patient. Neurostimulation leads in value because spinal cord and deep brain stimulation are heavily implant-driven, while neurointerventional devices advance fastest as thrombectomy reaches more regional patients. Movement disorders and public hospitals gain share as adaptive deep brain stimulation and state stroke programs widen access. New South Wales remains the largest region, and Queensland grows quickest on population inflow and expanding neurosurgical capacity. Local listings, portable scanners and brain-computer interface trials point to a durable shift in product mix and in the role of Australian innovators, rather than a short-lived procedural uplift.

Key Takeaways: Australia Neurology Devices Market

Ageing Population and Stroke Burden Anchor Demand

Revenue is on course to roughly double across the decade, from USD 320.00 million in 2025 to USD 653.42 million in 2035 at a 7.4% CAGR. More than 440,000 stroke survivors and a projected 72,000 strokes a year by 2050 keep device demand structurally high.

Neurointerventional and Adaptive Stimulation Lead Growth

Neurostimulation holds the largest share, but Neurointerventional Devices grow at an estimated 9.2% CAGR and Movement Disorders at an estimated 9.7% CAGR through 2035. The first adaptive deep brain stimulation patient in Australia, implanted in November 2025, signals wider uptake of sensing therapy.

Capital and Consolidation Reshape the Supplier Base

Local innovators are raising capital while global groups consolidate neurovascular portfolios, which widens choice for hospitals and sharpens competition on evidence and reimbursement.

• Saluda Medical and Epiminder listed on the ASX in December 2025
• Synchron closed a USD 200 million Series D in November 2025
• Boston Scientific agreed to acquire Penumbra in January 2026

Australia Neurology Devices Market Report Summary

Key Insight

Demand is shifting towards sensing stimulation, thrombectomy and portable diagnostics as the population ages and stroke care expands. New South Wales leads, and Queensland grows fastest.

Key Trends in the Australia Neurology Devices Market

The Australia neurology devices market is being reshaped by portable stroke imaging, closed-loop stimulation, adaptive deep brain stimulation and rechargeable implants.

September 2026 - EMVision Completes First In-Field Study of Its Stroke Scanner in Melbourne

• EMVision Medical Devices announced on 16 September 2026 that its First Responder scanner was tested with the Melbourne Mobile Stroke Unit at the Royal Melbourne Hospital.
• Ten patients were scanned in homes, ambulances and a workplace, with a mean scan time of 6.7 minutes and no device-related adverse events.
• A two-year memorandum of understanding with the Australian Stroke Alliance points to earlier stroke type identification outside hospital.

January 2026 - Saluda Medical Gains CE Certification for EVA Sensing Technology

• Saluda announced on 8 January 2026 that EVA received CE certification, and that the approval is recognised in Australia.
• A limited commercial release in Europe and Australia was planned for the first quarter of 2026, with full release later in the year.
• Real-time sensing lets spinal cord stimulation adjust to each patient, which strengthens the case for local use.

November 2025 - St Vincent's Hospital Implants Australia's First Adaptive Deep Brain Stimulator

• Neurologist Dr Joel Maamary treated a 61-year-old Parkinson's patient in November 2025, the first adaptive implant in Australia.
• The device senses abnormal brain signals and adjusts output in real time instead of stimulating continuously.
• Adaptive therapy may cut time spent in the off state, which supports growth in the Movement Disorders segment.

June 2025 - St Andrew's War Memorial Hospital Implants Abbott's Liberta RC Stimulator

• The Brisbane hospital reported on 26 June 2025 the first Australian implant of Abbott's rechargeable Liberta RC deep brain stimulator.
• Clinicians can adjust settings and push software updates remotely over Wi-Fi through the NeuroSphere Digital Care platform.
• Remote programming reduces clinic visits, which matters for patients who travel from regional Queensland.

Key Insight

Sensing stimulation, remote programming and portable stroke imaging are the main structural forces, while reimbursement timing and clinical evidence requirements remain the main risk to adoption speed.

Recent Market Developments in the Australia Neurology Devices Market

Recent developments, presented from the most recent, show epilepsy monitoring progress, neurovascular consolidation, brain-computer interface funding and new regulatory clearance for thrombectomy tools.

July 2026 - Epiminder Reaches 50 Enrolments in Its DETECT Epilepsy Monitoring Study

• The Melbourne company said on 16 July 2026 that it reached 50 enrolments in DETECT, ahead of guidance, using its implantable Minder device.
• Cash stood at A$75.8 million on 30 June 2026 after a A$125 million listing in December 2025.
• United States Medicare proposed a higher payment for the Minder procedure, which could support later Australian adoption.

January 2026 - Boston Scientific Agrees to Acquire Penumbra for USD 14.5 Billion

• Boston Scientific announced on 15 January 2026 a cash and stock offer of USD 374 per Penumbra share.
• The deal expands Boston Scientific's footprint in mechanical thrombectomy and neurovascular care.
• Penumbra reported revenue of USD 390.0 million in the June 2026 quarter, showing the scale of stroke device demand.

November 2025 - Synchron Raises USD 200 Million to Advance Its Stentrode Brain-Computer Interface

• Synchron announced the Series D on 6 November 2025, with Australia's National Reconstruction Fund among new investors.
• The Stentrode has been placed in 10 patients across United States and Australian trials, and funds will accelerate pivotal trials.
• Local capital and trial experience may anchor high-skill neurotechnology jobs in Melbourne and Sydney.

April 2025 - Route 92 Medical Receives TGA Approval for Neurovascular Portfolio

• The company announced on 1 April 2025 that the Therapeutic Goods Administration approved its HiPoint and FreeClimb reperfusion systems and Base Camp sheath.
• The products were introduced at the neuroradiology society meeting held in Perth from 27 to 29 March 2025.
• Wider tool choice for thrombectomy supports growth in Neurointerventional Devices.

Key Insight

Epilepsy monitoring milestones, large neurovascular acquisitions, brain-computer interface funding and new regulatory clearances show suppliers positioning for closed-loop therapy and stroke intervention throughout the forecast period.

Australia Neurology Devices Industry Segmentation

The Expert Market Research’s report on the Australia Neurology Devices Market offers a detailed analysis of the market based on the following segments.

Market Breakup by Product Type

• Neurostimulation Devices
• Neurointerventional Devices
• Neuromonitoring and EEG Devices
• Neurosurgical and CSF Management Devices
• Others

Neurostimulation Devices lead on value, in our estimate, growing at an estimated 7.8% CAGR through 2035 as Abbott's rechargeable Liberta RC, implanted in Brisbane in June 2025, and Saluda's EVA sensing, certified in January 2026, widen the range. Neurointerventional Devices grow fastest at an estimated 9.2%, aided by Route 92 Medical's TGA approval of April 2025. Neuromonitoring and EEG Devices grow at 6.8%, with Epiminder's Minder reaching 50 DETECT enrolments in July 2026. Neurosurgical and CSF Management Devices grow at 5.2% on steady shunt and cranial procedures.

Market Breakup by Application

• Chronic Pain
• Stroke and Cerebrovascular Disorders
• Movement Disorders
• Epilepsy
• Others

Chronic Pain leads in value, in our estimate, growing at 7.0% as spinal cord stimulation is Saluda's core indication. Stroke and Cerebrovascular Disorders grow at 8.1%, supported by EMVision's September 2026 field study with the Melbourne Mobile Stroke Unit. Movement Disorders grow fastest at an estimated 9.7% CAGR through 2035, after Australia's first adaptive deep brain stimulation in November 2025. Epilepsy grows at 9.1% as implantable monitoring matures. Others include traumatic brain injury and sleep-related disorders, growing at 5.4%.

Market Breakup by End User

• Public Hospitals
• Private Hospitals
• Specialist Neurology and Neurosurgery Clinics
• Research and Academic Institutes
• Others

Private Hospitals lead, in our estimate, because elective implants such as St Andrew's Brisbane Liberta RC procedure of June 2025 are concentrated there, and they grow at 7.2%. Public Hospitals grow fastest at an estimated 8.6% CAGR through 2035, as state stroke services adopt mobile units and thrombectomy. Specialist Neurology and Neurosurgery Clinics grow at 7.6% on outpatient monitoring and programming. Research and Academic Institutes grow at 6.4%, supported by trials such as Synchron's Stentrode, which has been placed in 10 patients across United States and Australian studies.

Market Breakup by Region

• New South Wales
• Victoria
• Queensland
• Western Australia
• Others

New South Wales dominates, in our estimate, because it hosts the largest hospital network, and it grows at an estimated 7.0% CAGR through 2035 from a large, mature base. Victoria grows at 7.3%, anchored by Epiminder and the Melbourne Mobile Stroke Unit. Queensland is the fastest-growing region at an estimated 8.4%, as Brisbane centres adopt new stimulators. Western Australia grows at 7.9%, hosting the March 2025 neuroradiology meeting. Others, covering the remaining states and territories, are grouped because each is a small volume market, and grow at 6.9%.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Competitive Landscape in the Australia Neurology Devices Market

Competition combines global device groups with Australian innovators. Entry barriers include clinical evidence, Therapeutic Goods Administration listing, private insurer reimbursement on the prostheses list, surgeon training and hospital relationships across public and private systems.

Medtronic

Medtronic, headquartered in Dublin, Ireland, supplies deep brain stimulation, spinal cord stimulation and neurovascular products to Australian hospitals through its Australasian operations. On 24 February 2025 the company announced United States approval for its BrainSense Adaptive deep brain stimulation system, the first of its kind for Parkinson's disease. Australia's first adaptive implant followed in November 2025, reflecting the technology's move into local practice.

Abbott

Abbott, headquartered in Abbott Park, Illinois, sells neuromodulation systems for chronic pain and movement disorders in Australia. In June 2025 St Andrew's War Memorial Hospital in Brisbane became the first Australian hospital to implant its Liberta RC rechargeable deep brain stimulator, performed by Professor Peter Silburn and Dr Terry Coyne. The system supports remote programming through NeuroSphere Digital Care, reducing clinic visits.

Saluda Medical

Saluda Medical is an Australian neurostimulation company developing the Evoke closed-loop spinal cord stimulation system, which reads evoked neural responses in real time. It listed on the Australian Securities Exchange on 5 December 2025, raising A$230.8 million at A$2.65 per share. On 8 January 2026 its EVA sensing technology received CE certification, recognised in Australia, with limited release in Europe and Australia planned for early 2026.

Epiminder

Epiminder, based in Melbourne, develops the Minder implantable continuous EEG monitoring system for people with epilepsy. It completed a A$125 million listing in December 2025 and announced the first United States implant in January 2026. On 16 July 2026 it reported 50 enrolments in its DETECT study, with cash of A$75.8 million at 30 June 2026 and commercial sales targeted for early 2028.

Other players operating in the Australia neurology devices market include Boston Scientific, Penumbra, Synchron, EMVision, and Stryker, alongside regional distributors, specialist importers, local software developers and contract manufacturers supplying neurostimulation, neurointerventional and monitoring products to public hospitals, private hospitals and clinics across Australia.

Key Insight

Competition rests on clinical evidence, regulatory listing, reimbursement and surgeon relationships rather than price alone, while acquisitions and local listings could reshape positions among established and emerging suppliers.